Literature DB >> 20799911

Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.

Hans J Nielsen1, Nils Brünner, Lars N Jorgensen, Jesper Olsen, Hans B Rahr, Knud Thygesen, Ute Hoyer, Søren Laurberg, Petra Stieber, Marinus A Blankenstein, Gerard Davis, Barry L Dowell, Ib J Christensen.   

Abstract

OBJECTIVE: The combination of plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) and carcinoembryonic antigen (CEA) may be valuable biomarkers for early detection of colorectal cancer (CRC). A prospective, population based study was performed to validate this hypothesis.
MATERIAL AND METHODS: Individuals (n = 4509) referred for large bowel endoscopy due to symptoms of CRC were prospectively included. Baseline data and concurrent diseases were recorded. The primary endpoint was detection of CRC and findings at examinations were recorded using International Classification of Diseases-10 codes. Plasma was obtained before endoscopy and TIMP-1 and CEA levels were determined after the inclusion of all individuals.
RESULTS: Findings were based on sigmoidoscopy in 1766 and colonoscopy in 2743 individuals. Colon cancer (CC) was detected in 184 and rectal cancer in 110 individuals. Ten individuals with other cancers, 856 with adenomas and 1176 with non-neoplastic findings were also detected. The biomarker levels were increased in a variety of diseases including CRC compared to individuals without any findings at endoscopy. A multivariable analysis demonstrated that both markers were significant and independent detectors of CRC. Combining both biomarkers, independent contributions from each (TIMP-1, odds ratio (OR) = 1.8 (95% confidence interval (CI): 1.4-2.2), p < 0.0001; CEA < 5 ng/ml, OR = 1.6, 1.3-1.9, or ≥ 5 ng/ml, OR = 2.3, 95% CI: 1.9-2.7 (p < 0.0001)) were obtained. Subgroup analysis of individuals examined by colonoscopy with CC as the endpoint showed that combining both biomarkers, independent contributions from each (TIMP-1, OR = 2.5, 95% CI: 1.8-3.4, p < 0.0001; CEA < 5 ng/ml, OR = 1.4, 95% CI: 1.1-1.8, and CEA ≥ 5 ng/ml, OR = 2.3, 95% CI: 1.8-3.0 (p < 0.0001)) were obtained.
CONCLUSIONS: This prospective validation study supports the use of the combination of plasma TIMP-1 and CEA protein measurements as a potential aid in early detection of CRC and specifically of CC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20799911     DOI: 10.3109/00365521.2010.513060

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  30 in total

1.  Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients.

Authors:  Kristina Schee; Kjersti Flatmark; Ruth Holm; Kjetil Boye; Elisabeth Paus
Journal:  Tumour Biol       Date:  2011-10-18

2.  Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

Authors:  Bodil E Engelmann; Annika Loft; Andreas Kjær; Hans J Nielsen; Thomas A Gerds; Eric V Benzon; Nils Brünner; Ib J Christensen; Susanne H Hansson; Niels H Holländer; Michael H Kristensen; Johan Löfgren; Elena Markova; Carsten Sloth; Liselotte Højgaard
Journal:  Oncologist       Date:  2014-01-22

3.  Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material.

Authors:  Martin Lundberg; Stine Buch Thorsen; Erika Assarsson; Andrea Villablanca; Bonnie Tran; Nick Gee; Mick Knowles; Birgitte Sander Nielsen; Eduardo González Couto; Roberto Martin; Olle Nilsson; Christian Fermer; Jörg Schlingemann; Ib Jarle Christensen; Hans-Jorgen Nielsen; Björn Ekström; Claes Andersson; Mats Gustafsson; Nils Brunner; Jan Stenvang; Simon Fredriksson
Journal:  Mol Cell Proteomics       Date:  2011-01-17       Impact factor: 5.911

Review 4.  Management of colorectal cancer and diabetes.

Authors:  Caroline Yao; Guy F Nash; Tamas Hickish
Journal:  J R Soc Med       Date:  2013-12-13       Impact factor: 5.344

5.  Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.

Authors:  Hong In Yoon; Woong Sub Koom; Yong Bae Kim; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Sang Joon Shin; Joong Bae Ahn; Ki Chang Keum
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-04       Impact factor: 4.553

Review 6.  Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Authors:  Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 7.  Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Authors:  Kim Y C Fung; Edouard Nice; Ilka Priebe; Damien Belobrajdic; Aloke Phatak; Leanne Purins; Bruce Tabor; Celine Pompeia; Trevor Lockett; Timothy E Adams; Antony Burgess; Leah Cosgrove
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

8.  Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients.

Authors:  Ping-Ping Wu; Ji-Hong Zou; Ri-Ning Tang; Yao Yao; Cheng-Zhong You
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

9.  Differences in carcinoembryonic antigen levels between colon and rectal cancer.

Authors:  Yunlong Ding; Weibo Xuan; Chunlin Chen; Zhe Chen; Ziyi Yang; Yunfei Zuo; Shuangyi Ren
Journal:  Mol Clin Oncol       Date:  2014-04-30

Review 10.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.